Accordingly, the immune-infiltrated Vgll3+ model showed a more robust response to the standard regimen of doxorubicin compared to the immune-excluded Ccne1+ model (Fig. 1g, h), suggesting that an inflamed sarcoma microenvironment may be favorable for chemotherapy responses. The gene discussed is VGLL3; the disease is sarcoma.